[ad_1]
Data includes the first real-world evidence on alternate bladder EpiCheck® and cystoscopy for monitoring non-muscle invasive bladder cancer (NMIBC)
Nucleix, a liquid biopsy company that revolutionizes cancer treatment by detecting diseases earlier, today announced data from two abstracts at the 36th European Association of Urology (EAU) Virtual Conference, these abstracts include its bladder EpiCheck® test .
The first article titled “Real World Evidence of Alternating Cystoscopy/Cytology and Bladder EpiCheck in NMIBC Monitoring” shows the results of a pilot conducted at Radboud University Medical Center, which evaluated Cystoscopy/Cytology and Bladder EpiCheck The feasibility and clinical outcome of alternate non-muscle invasive bladder cancer (NMIBC) monitoring. In order to reduce the burden of invasive and expensive standard monitoring methods for patients, urine is collected at home and transported to a central laboratory for bladder EpiCheck testing. In a preliminary analysis, follow-up patients showed that the Bladder EpiCheck had a sensitivity of 100% and a specificity of 88% for high-grade lesions, thus avoiding 76% of unnecessary cystoscopy. The authors concluded that this modified surveillance program is safe and cost-effective due to the high sensitivity and high specificity of Bladder EpiCheck for high-grade diseases.
“This is the first published evidence of an alternate schedule for the use of urine markers, such as Bladder EpiCheck, cystoscopy or cytology. Because of Bladder EpiCheck’s high sensitivity and specificity for high-grade diseases, and well-planned infrastructure , All high-grade tumors, including muscle invasive tumors, are…
The full story on Benzinga.com
[ad_2]
Source link
